Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Clinical evidence

ANX007-GLA-02

30 evidence topics · 4 sources

Objective
Location and study date
Registry dates for the phase 1b study
MilestoneRegistry record
Study start (actual)“2018-07-25”
Primary completion (actual)“2019-06-03”
Study completion (actual)“2019-06-03”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics of the phase 1b study by arm
CharacteristicSham (n = 6)ANX007 2.5 mg (n = 6)ANX007 5.0 mg (n = 5)Overall (n = 17)
Age, mean (SD), yr“70.2 (22.8)”View highlighted excerpt for this quote“60.3 (16.2)”View highlighted excerpt for this quote“74.0 (8.0)”View highlighted excerpt for this quote“67.8 (17.2)”View highlighted excerpt for this quote
Age, median (min, max), yr“79.5 (24, 82)”View highlighted excerpt for this quote“58.5 (35, 78)”View highlighted excerpt for this quote“74.0 (65, 86)”View highlighted excerpt for this quote“75.0 (24, 86)”View highlighted excerpt for this quote
Male, n (%)“4 (66.7)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“8 (47.1)”View highlighted excerpt for this quote
Female, n (%)“2 (33.3)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote“3 (60.0)”View highlighted excerpt for this quote“9 (52.9)”View highlighted excerpt for this quote
Black/African American, n (%)“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.9)”View highlighted excerpt for this quote
Asian, n (%)“1 (16.7)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“1 (20.0)”View highlighted excerpt for this quote“3 (17.6)”View highlighted excerpt for this quote
White, n (%)“5 (83.3)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote“4 (80.0)”View highlighted excerpt for this quote“13 (76.5)”View highlighted excerpt for this quote
Weight, mean (SD), kg“74.8 (20.3)”View highlighted excerpt for this quote“79.7 (10.1)”View highlighted excerpt for this quote“88.4 (15.0)”View highlighted excerpt for this quote“80.5 (15.8)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events in the phase 1b study by arm
n (%)Sham (n = 6)ANX007 2.5 mg (n = 7)ANX007 5 mg (n = 5)Overall (n = 18)
Any TEAE“2 (33.3)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“6 (33.3)”View highlighted excerpt for this quote
Ocular disorders“2 (33.3)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“6 (33.3)”View highlighted excerpt for this quote
Infection“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Injury“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Treatment-related TEAE“2 (33.3)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“5 (27.8)”View highlighted excerpt for this quote
Conjunctival hemorrhage“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0)”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Conjunctival hyperemia“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Eye irritation“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote
Foreign body sensation in eyes“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Ocular hyperemia“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Vision blurred“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small sample, and short follow-up

ANX007-GLA-02 enrolled participants with primary open-angle glaucoma, a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. Seventeen participants received study treatment (sham, 6; 2.5 mg, 6; 5 mg, 5), follow-up lasted 12 weeks with 2 injections given 4 weeks apart, and no formal comparisons or hypothesis testing were planned, so the results are descriptive. The safety table lists 7 participants in the 2.5-mg column and 18 overall, while the text reports 6 participants treated with 2.5 mg and 17 treated overall. Target engagement was measured in aqueous humor, which the authors state is “anticipated to represent” inhibition of C1q in the retina, supported by nonhuman primate data on file. The 5-mg dose was given in 100 μL in this study, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose. Low-level anti-drug antibody positivity was detected in 7 participants, including 1 in the sham group, which the authors attribute to likely false positives in the assay.